MRPL19

Across TCGA pan-cancer cohorts, MRPL19 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of MRPL19’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MRPL19 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MRPL19 is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

BLCA, HNSC, and KIRC are the cancer types where MRPL19 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRPL19 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	All	+1.099	<.001	12	view →
HNSC	Male	IV	+0.809	<.001	12	view →
KIRC	Male	II,III,IV	−0.675	<.001	11	view →
LUAD	Male	II,III,IV	+1.050	<.001	9	view →
STAD	Male	II,III,IV	+0.894	<.001	9	view →
LUSC	Male	II,III,IV	+1.031	<.001	8	view →
BRCA	All	II,III,IV	+0.526	<.001	8	view →
THCA	All	II,III,IV	−0.475	<.001	8	view →
KICH	Female	II,III,IV	−1.467	<.001	7	view →
UCEC	All	II,III,IV	+0.990	<.001	6	view →
LIHC	All	All	+0.384	<.001	5	view →
CHOL	All	All	+0.628	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

MRPL19–BLCA

Open the BLCA breakdown →